Tristan Jervis’ Post

Join us for this webinar as our panel of experts provide a thorough understanding of how clinical trial outcomes impact biopharma company valuations. Speakers Catherine Beech MB,ChB,OBE, Amir Hefni, William Harries and Joe Hopcraft will explore the underlying drivers of these impacts, such as trial results compared to investors’ prior expectations, development phase at readout, therapy area, and trial design. https://lnkd.in/gjfAsrua #biotech

Positive clinical trial results boost Biopharma valuations, but not to the same degree as negative results lower them, and the degree of impact of valuation is influenced by the therapy area, nature of trial and other factors- this has all been robustly demonstrated in IQVIA’s recent white paper on how clinical trial results impact biopharma valuations - link below. But how can Biopharma use these insights to design trials which maximise positive value impact? Join our webinar which brings the paper’s author William Harries together with #Biopharma CEOs and IQVIA experts to discuss. https://lnkd.in/ezs77Xqe

Developing novel therapies to address unmet patient need is crucial in the biopharmaceutical industry. Bringing a new therapy to market requires an estimated $3.1 billion, with an 11% success rate from phase 1 through regulatory submission. A recent white paper by my IQVIA colleagues Markus Gores, William Harries Francesco Capuzzi, PhD delves into how clinical trial outcomes impact company valuations, especially for emerging biopharma companies with <$1 billion market capitalization. These companies are highly responsive to trial results, as their value is concentrated in their pipeline, often with just a single asset. The study highlights that EBP valuations are significantly more sensitive to clinical trial readouts, compared to big pharma companies. Explore more insights here: [Link to the white paper] #Biopharma #ClinicalTrials #CompanyValuations #Innovation #BigPharma #LifeSciences #Consulting #IQVIA #Valuation

As biotech and biopharma companies face increased pressure to modernize clinical trials, a strategic partnership with an experienced CRO is proving intrinsic to success. Overcome barriers to completion with guidance you can trust. https://bit.ly/4bUYdnQ #biotech #clinicaltrials

// 5 key success factors for your clinical trials // Emerging Biopharma & Biotech? With so much at stake in your clinical trials, consider partnering with an eCOA and DCT expert! Discover the 5 key success factors for your clinical trials: https://bit.ly/3rFGPSM #kayentis #eCOA #DCT #clinicaltrials #EmergingBioPharma

After the worst downturn in biotech history, are there finally signs of optimism heading into the second half? Join BioCentury Inc. and Oppenheimer & Co. Inc. for an in-depth discussion with investors and pharma dealmakers about where the biotech market is headed.   Register for this complimentary webinar to join live and ask questions, or watch the recorded version at your convenience: https://lnkd.in/gkZBPBaq Moderator: Stephen Hansen, BioCentury Inc. Panelists: Ario Arabi, Novartis Nina Kjellson, Canaan Partners Andrew W. Lam, PharmD, Ally Bridge Group Michael Margolis, Oppenheimer & Co. Inc. Nimish Shah, Venrock #biotech #biopharma #pharma #investors #dealmakers #capitalmarkets #VCs #capitalmarketspreview

The multi-billion-dollar BioPharma industry is undergoing more change than ever before. The impending presidential election, ever escalating innovations in tech and AI, new drug legislation, and inflation all have an impact and it’s extremely challenging to predict the net effect.        In our latest industry insight report, we investigate broader industry trends and also delve into talent insights for Massachusetts; the state that continues to be a beacon of innovation and growth. 👀 Sneak preview: from our research, Rapport Therapeutics, Ardelyx, Inc., Flagship Pioneering and Sumitomo Pharma America, Inc. were the fastest growing companies in their size bracket.  Read the full report to find out who else featured, link in the comments ⬇

Come learn about our microbial and mammalian CDMO capabilities!

We are proud to share that we have helped a top 10 CMO secure 25 new business meetings with pharma and biotech leaders while travelling this week. Since 2013, we have helped our clients connect with the right decision-makers in the #pharma, #biotech, and #medtech industries. We look forward to continuing our mission of connecting people intelligently in the pharma and biotech service providers. 👉 𝗜𝗳 𝘆𝗼𝘂'𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝗸𝗻𝗼𝘄 𝗺𝗼𝗿𝗲 𝘀𝗲𝗻𝗱 𝘂𝘀 𝗮 𝗺𝗲𝘀𝘀𝗮𝗴𝗲 𝗼𝗻 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻. 👏Celebrating 10 years of connecting people in the pharma and biotech industry! #PharmaTargeting - The home of Pharma Service Providers. #pharmaserviceproviders Anil Kumar

Geez, using the term "flop" seems kind of harsh, but I get it. ;) At least the author added this: You can learn as much about how to develop a drug from past failures as you can from success. When you look at the biopharma pipeline, there are plenty of lessons learned to choose from. #clinicaltrials #clinicalresearch #medicalcommunications #medcomms #biotech https://lnkd.in/eDaaFYnm